Measles Treatment According to Australian Guidelines
Measles treatment in Australia is primarily supportive care, with vitamin A supplementation for children, and post-exposure prophylaxis using MMR vaccine (within 72 hours) or immunoglobulin (within 6 days) for susceptible contacts.
Immediate Clinical Management
Supportive Care
The cornerstone of measles treatment is supportive management, as there is no specific antiviral therapy available 1, 2. This includes:
- Fever management with antipyretics
- Hydration maintenance
- Monitoring for complications (pneumonia, encephalitis, secondary bacterial infections)
- Respiratory support if needed for pneumonia or respiratory distress
Vitamin A Supplementation
Vitamin A should be administered to children with measles to reduce mortality 2. This is particularly important for:
- Children under 2 years of age
- Those with vitamin A deficiency
- Hospitalized patients
The evidence strongly supports vitamin A treatment in younger children as it decreases measles-related mortality 2.
Post-Exposure Prophylaxis
For Exposed Contacts - Decision Algorithm
Within 72 hours of exposure:
- MMR vaccine is preferred for most susceptible persons ≥12 months of age 3
- This applies to exposures in day care, schools, colleges, and healthcare facilities
- Vaccine may provide protection if given within this window 3
Within 6 days of exposure (if vaccine not given or contraindicated):
- Immunoglobulin (IG) is indicated for high-risk susceptible contacts 3:
- Infants ≤12 months
- Pregnant women
- Immunocompromised persons
- Household contacts who missed the 72-hour vaccine window
Immunoglobulin Dosing
- Standard dose: 0.25 mL/kg body weight (maximum 15 mL) 3
- Immunocompromised persons: 0.5 mL/kg body weight (maximum 15 mL) 3
- IGIV recipients: 100 mg/kg within 3 weeks before exposure is sufficient 3
Special Populations
Immunocompromised Patients
- Should receive IG prophylaxis regardless of vaccination status after measles exposure 3
- MMR vaccine is contraindicated for post-exposure prophylaxis in this group 3
- No specific antiviral treatment available, though ribavirin has been mentioned in severe cases 1
Pregnant Women
- MMR vaccine is contraindicated for post-exposure prophylaxis 3
- IG should be administered if exposed 3
Infants
- Infants <6 months usually have maternal antibody protection 3
- If mother has measles, all unvaccinated children in household should receive IG 3
- Infants vaccinated before 12 months must be revaccinated after their first birthday with two MMR doses separated by ≥28 days 3
Infection Control in Healthcare Settings
Critical measures for Australian healthcare facilities 1, 4:
- Immediate notification to public health authorities when measles is suspected 4
- Airborne precautions: N-95 masks and airborne infection isolation rooms 1
- Contact tracing should be initiated immediately 4
- Urgent laboratory testing: Serum measles-specific IgM and IgG antibodies 4
Key Clinical Pitfalls
Don't delay public health notification - Australian guidelines emphasize immediate reporting to enable contact tracing 4
Don't miss the 72-hour vaccine window - After this, IG becomes the primary option for susceptible contacts 3
Don't forget vitamin A - This evidence-based intervention reduces mortality in children 2
Don't assume immunity - Even vaccinated individuals can contract measles; 12.1% of Australian cases had received ≥2 doses 5
Consider travel history - Most Australian cases (55.1% acquired overseas) are linked to returning travelers, particularly from Indonesia, Philippines, and India 5
Australian Context
Australia achieved measles elimination in 2014, with most cases now imported by unvaccinated travelers aged 20-49 years 5. The average notification rate is 0.4 per 100,000 population per year, with peaks following school holiday periods when international travel increases 5. Maintaining high two-dose MMR coverage (93-95%) is essential to prevent endemic transmission re-establishment 2, 5.